Curis (NASDAQ:CRIS) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Curis (NASDAQ:CRIS) in a report issued on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Curis in a report on Tuesday, December 10th.

Curis Price Performance

Shares of NASDAQ CRIS opened at $2.84 on Thursday. The firm’s 50-day moving average price is $3.19 and its 200-day moving average price is $4.08. The company has a market cap of $24.05 million, a PE ratio of -0.36 and a beta of 3.49. Curis has a 52-week low of $2.57 and a 52-week high of $17.49.

Hedge Funds Weigh In On Curis

Institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in shares of Curis in the 4th quarter worth approximately $35,000. Millennium Management LLC raised its stake in Curis by 92.6% during the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 12,287 shares during the period. Focused Wealth Management Inc raised its stake in Curis by 9.5% during the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 5,138 shares during the period. Geode Capital Management LLC raised its stake in Curis by 27.3% during the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 17,820 shares during the period. Finally, Alyeska Investment Group L.P. bought a new stake in Curis during the 4th quarter worth approximately $607,000. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.